Related Experiment Video
Updated: Apr 15, 2026
07:14
A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation
Published on: July 13, 2018
15.5K
Cryptotanshinone protects against adriamycin-induced mitochondrial dysfunction in cardiomyocytes
Yanshan Zhang1, Liang Chen2, Fan Li3
1a Department of Tumor Surgery , Wuwei Tumor Hospital , Wuwei, Gansu PR China .
Pharmaceutical Biology
|April 11, 2015
Summary
Cryptotanshinone (CRY) protects heart cells from Adriamycin (ADR)-induced mitochondrial damage. This antioxidant may be a potential drug for preventing heart conditions caused by ADR.
Area of Science:
- Cardiovascular Research
- Mitochondrial Biology
- Pharmacology
Background:
- Adriamycin (ADR) is known to cause serious side effects, notably cardiomyopathy.
- Cryptotanshinone (CRY) is a safe and widely used antioxidant with a high maximum tolerated dose in rats.
Purpose of the Study:
- To investigate the protective effects of CRY against Adriamycin (ADR)-induced mitochondrial dysfunction in cardiomyocytes.
- To evaluate CRY's potential as a cardioprotective agent.
Main Methods:
- Rats were administered CRY (50 mg/kg, p.o.) for 20 days.
- Mitochondrial function markers including respiratory chain complex activities, ATP generation, mitochondrial membrane potential (MMP), and oxidative stress were assessed.
- Mitochondrial biogenesis factors were also analyzed in control, ADR-treated, and ADR + CRY-treated groups.
Main Results:
- CRY treatment significantly enhanced ATP production and mitochondrial membrane potential (MMP).
- CRY inhibited superoxide anion free radical generation and augmented nitric oxide (NO) and glutathione peroxidase (GSH-PX) activity.
- CRY promoted mitochondrial biogenesis factors like PGC-1α, NRF-1, and TFAM.
Conclusions:
- Cryptotanshinone (CRY) demonstrates significant cardioprotective effects against Adriamycin (ADR)-induced mitochondrial dysfunction.
- CRY's ability to restore mitochondrial function and biogenesis suggests its potential as an ideal therapeutic agent for ADR-induced cardiotoxicity.
